NCT04469998

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

A Phase I/II, Randomized, Double-Masked, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of AXR-270 Topical Eyelid Cream in Treating Posterior Blepharitis Associated With Meibomian Gland Dysfunction

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 129 (actual)
• Sponsor: AxeroVision, Inc. · Industry
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating posterior blepharitis associated with Meibomian Gland Disease (MGD)

Detailed description

AXR201901 is a multicenter, randomized, double-masked, vehicle-controlled study of AXR-270 cream and AXR-270 vehicle in subjects with signs and symptoms of posterior blepharitis associated with meibomian gland dysfunction

Conditions

• Posterior Blepharitis
• Meibomian Gland Dysfunction

Interventions

Type	Name	Description
DRUG	AXR-270 Low Dose	AXR-270 Topical Eyelid Cream
DRUG	AXR-270 High Dose	AXR-270 Topical Eyelid Cream
DRUG	AXR-270 Vehicle	AXR-270 Topical Eyelid Cream Vehicle

Timeline

• Start date: 2020-06-16
• Primary completion: 2020-12-01
• Completion: 2020-12-31
• First posted: 2020-07-14
• Last updated: 2023-07-21
• Results posted: 2023-07-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study